文献速递皮肤肿瘤皮肤感染

慢性淋巴细胞白血病患者皮肤鳞状细胞癌的检查点免疫治疗:两名接受PD-1抑制剂治疗男性的不同结局

Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-01-01

本文报告两名患有慢性淋巴细胞白血病(CLL)且无治疗指征的局部晚期或转移性皮肤鳞状细胞癌(cSCC)男性患者,均接受PD-1抑制剂帕博利珠单抗治疗,但治疗结局不同。尽管CLL可能导致免疫抑制状态,两名患者仍接受了免疫治疗。

要点

  • 慢性淋巴细胞白血病(CLL)患者因基础血液肿瘤常无法进入PD-1抑制剂临床试验。
  • 两名CLL合并局部晚期或转移性cSCC男性均接受帕博利珠单抗治疗,结局不同。
  • cSCC突变负荷高,PD-1抑制剂为其全身治疗的有前景候选药物。

核心结论

  • 两名CLL合并局部晚期或转移性cSCC患者接受帕博利珠单抗治疗后出现不同的治疗结局。

研究设计与样本

  • 本文为病例报告,报告两名患有CLL多年且无治疗指征的局部晚期或转移性cSCC男性患者。

主要发现

  • 两名患者均接受PD-1抑制剂帕博利珠单抗治疗,但治疗结局不同。

关键数值与推荐

  • PD-1抑制剂帕博利珠单抗、纳武利尤单抗和西米普利单抗在局部晚期或转移性cSCC的全身治疗中显示出疗效,西米普利单抗于2018年获美国食品药品监督管理局(FDA)批准、2019年获欧洲药品管理局(EMA)批准。
  • cSCC被认为是所有实体瘤中突变负荷最高的癌种之一,突变负荷与PD-1抑制剂应答率呈正相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cutaneous squamous cell carcinoma (cSCC) numbers among the most common types of skin cancer and is known as one of the cancer entities with the highest mutational burden among all solid tumours. Due to the positive correlation between mutational burden and response rate to inhibitors of the programmed cell death 1 (PD-1), those inhibitors are considered promising candidates for the systemic therapy of cSCC. Recently, the PD-1 inhibitors pembrolizumab, nivolumab and cemiplimab demonstrated efficacy in the systemic treatment of locally advanced or metastatic cSCC leading to the approval of cemiplimab by the FDA (U.S. Food and Drug Administration) in 2018 and the EMA (European Medicines Agency) in 2019. Patients with haematological malignancies tend to develop skin cancers of high aggressiveness, enhanced cumulative recurrence rate and higher rates of metastases with subsequent death. Chronic lymphocytic leukaemia (CLL) is the most frequent type of leukaemia in the United States and Europe with the majority of patients older than 50 years of age. This neoplasm predominantly originates from B -cells leading to an impaired immune system of the patient. Although CLL is a B-cell malignancy, studies have also described the involvement of T cells in the pathogenesis and progression of the disease with contradictory findings on the effects of PD-1 inhibitors in CLL. Due to their underlying hematologic malignancy, these patients have commonly no access to PD-1 inhibitor trials for treatment of advanced cSCC. We report on two patients with locally advanced or metastatic cSCC. Both patients had been suffering from a CLL for many years without indication for treatment. Despite a potential immunosuppressive state of the patients due to their CLL, both were treated with the PD-1 inhibitor pembrolizumab resulting in different therapy outcomes.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Jansen P, Lodde GC, Wetter A, et al. Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors. J Eur Acad Dermatol Venereol. 2022. PMID: 34855243. doi:10.1111/jdv.17405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。